Zhiqiang Yang

This inventor holds 10 USPTO granted patents and 5 published patent applications and 11 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Angex Pharmaceutical, Inc.. Active years: 2017-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhiqiang Yang. Retrieved from https://idiyas.com/inventor/zhiqiang-yang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 5)

% Patents Active = 80.0

EPO Patents = 11 (Patent Applications = 11)

Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 9(Granted Patents)

Company Filing History:

7 out of 2,405

Merck Sharp + Dohme Corp.

patents

3 out of 3

Angex Pharmaceutical, Inc.

patents

Years Active: 2017-2022

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11358949 - Carbamate and urea compounds as multikinase inhibitors (2022-06-14),

2. 11180497 - Cyclic compounds as immunomodulating agents (2021-11-23),

3. 11098046 - Macrocyclic compounds as TRK kinase inhibitors and uses thereof (2021-08-24),

4. 11058775 - Insulin dimer-incretin conjugates (2021-07-13),

5. 10925876 - Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders (2021-02-23),

6. 10780092 - Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators (2020-09-22),

7. 10322140 - Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists (2019-06-18),

8. 10213429 - Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators (2019-02-26),

9. 9822130 - Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators (2017-11-21),

10. 9701669 - Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists (2017-07-11),

Title: Zhiqiang Yang: Innovator in Pharmaceutical Chemistry

Introduction

Zhiqiang Yang is an accomplished inventor based in Westfield, NJ, known for his contributions to pharmaceutical chemistry. With a remarkable portfolio of 10 patents, Yang's work focuses on innovative compounds designed to combat various diseases, particularly through the modulation of kinases and immune responses.

Latest Patents

One of Yang's latest patents is titled "Carbamate and urea compounds as multikinase inhibitors." This patent describes the development of novel carbamate and urea compounds that serve as multikinase inhibitors. The disclosed pharmaceutical compositions utilizing these compounds aim to treat cancer, infectious diseases, and other disorders linked to kinases.

Additionally, Yang has developed another patent entitled "Cyclic compounds as immunomodulating agents." This patent showcases the creation of novel IDO inhibitors and the methods for their preparation. The resulting pharmaceutical compositions are designed to offer therapeutic solutions for cancer, infectious diseases, and various immune-related disorders.

Career Highlights

Throughout his career, Zhiqiang Yang has contributed significantly to the pharmaceutical industry by working with noteworthy companies. He has held positions at Merck Sharp & Dohme Corporation and Angex Pharmaceutical, Inc., where he collaborated with other research professionals in the development of innovative drug therapies.

Collaborations

Zhiqiang Yang has worked alongside talented colleagues, including Guizhen Dong and Subharekha Raghavan. These collaborations have played a vital role in advancing research and developing effective pharmaceutical solutions.

Conclusion

Zhiqiang Yang's innovative spirit and dedication to pharmaceutical chemistry have positioned him as a prominent inventor in his field. His patents continue to pave the way for advancements in treatment options for cancer and infectious diseases, showcasing the essential role of inventors in the ongoing fight against complex health challenges.

Profile summary based on public USPTO records.